Cargando…

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma

The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved phar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suarez, Lorena P., Kemper, Gregory M., Duggan, Megan C., Stiff, Andrew, Noel, Tiffany C., Markowitz, Joseph, Luedke, Eric A., Yildiz, Vedat O., Yu, Lianbo, Jaime-Ramirez, Alena Cristina, Karpa, Volodymyr, Zhang, Xiaoli, Carson, William E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348384/ https://www.ncbi.nlm.nih.gov/pubmed/27783987 http://dx.doi.org/10.18632/oncotarget.12791

Ejemplares similares

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
por: Augello, Giuseppa, et al.
Publicado: (2018)

MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma
por: Xu, Hao, et al.
Publicado: (2022)

2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
por: Ololade, Shafiu O, et al.
Publicado: (2019)

2238. Effect of Cefazolin Breakpoint Update in Susceptibility Reports on Antimicrobial Use
por: Buckley, Valerie, et al.
Publicado: (2023)

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2019)

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases
por: Rubattu, Speranza, et al.
Publicado: (2018)

Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2021)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment
por: Misra, Shrilekha, et al.
Publicado: (2020)

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.
por: Martínez, Javier Alberto Rojas, et al.
Publicado: (2023)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

The Relationship between Natriuretic Peptide Precursor a Gene T2238C Polymorphism and Hypertension: A Meta-Analysis
por: Niu, Wenquan
Publicado: (2011)

PReS-FINAL-2238: PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome: results from the Eurofever registry
por: Caorsi, R, et al.
Publicado: (2013)

2238. Estimating the impact of antibiotic exposure on antibiotic resistance in uncomplicated UTI using machine learning causal inference
por: Kanjilal, Sanjat, et al.
Publicado: (2022)

Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration
por: Markowitz, Joseph, et al.
Publicado: (2018)

Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration
por: Markowitz, Joseph, et al.
Publicado: (2017)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Broad and potent antiviral activity of the NAE inhibitor MLN4924
por: Le-Trilling, Vu Thuy Khanh, et al.
Publicado: (2016)

Prevalence of HIV and other sexually transmitted infections and their association with sexual practices and substance use among 2238 MSM in Lebanon
por: Assi, Ayman, et al.
Publicado: (2019)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
por: Sampat, Parth J., et al.
Publicado: (2021)

Ixazomib-induced Sweet’s syndrome: A case report
por: Bellemare, Jeanne, et al.
Publicado: (2023)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

From the dual function lead AP2238 to AP2469, a multi-target-directed ligand for the treatment of Alzheimer's disease
por: Tarozzi, Andrea, et al.
Publicado: (2014)

The C2238/αANP Variant Is a Negative Modulator of Both Viability and Function of Coronary Artery Smooth Muscle Cells
por: Rubattu, Speranza, et al.
Publicado: (2014)

C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP
por: Carnevale, Roberto, et al.
Publicado: (2017)

MLN51 Stimulates the RNA-Helicase Activity of eIF4AIII
por: Noble, Christian G., et al.
Publicado: (2007)

Hybrid Breeding for MLN Resistance: Heterosis, Combining Ability, and Hybrid Prediction
por: Nyaga, Christine, et al.
Publicado: (2020)

The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance
por: Du, Meng-ge, et al.
Publicado: (2021)

2238. Immunogenicity and safety of four- vs. three-standard doses HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
por: Laksananun, Nattinee, et al.
Publicado: (2018)

PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN
por: Ropero, P., et al.
Publicado: (2022)

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2018)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

CERN: servono 20-26 mln euro per riparare acceleratore LHC
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_b6kh6q7qtkft43v8kq1c0hgbmg